BBIO: Strong growth outlook with multiple late-stage launches and expanding pipeline through 2027
The business is growing strongly, led by acoramidis and a late-stage pipeline with three major launches by 2027. ATTR-CM stabilizers are frontline, with Attruby set for greater market share. Launches in limb-girdle muscular dystrophy, ADH1, and achondroplasia are backed by focused strategies and fa…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.